Skip to main content
. Author manuscript; available in PMC: 2018 Mar 1.
Published in final edited form as: Med Clin North Am. 2017 Mar;101(2):333–350. doi: 10.1016/j.mcna.2016.09.006

Figure 2. How I evaluate and treat myelodysplastic syndrome.

Figure 2

In this schematic, I summarize my general approach to patients with MDS. I provide additional details on how I choose the dose/schedule of azacitidine and monitor for response on a practical level. Many patients at the beginning of therapy (e.g., first and second cycles) will need close monitoring of their blood counts (e.g., two or three times a week) but this is usually adjusted during later cycles based on a patient’s typical length and depth of nadir. Table 1: Prediagnostic stages toward myelodysplastic syndrome.